- Conditions
- Age-related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg
- Drug
- Lead sponsor
- Leonard Feiner, MD, PhD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Teaneck, New Jersey • Vauxhall, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 908
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 54
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
- Conditions
- Neovascular Wet Age-related Macular Degeneration (AMD)
- Interventions
- REGN2176-3
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Colorado Springs, Colorado • Boston, Massachusetts + 1 more
- Conditions
- Macular Degeneration
- Interventions
- Proparacaine Ophthalmic, Tetracaine Ophthalmic, Lidocaine 4%, Lidocaine 2% Injectable Solution
- Drug
- Lead sponsor
- Lahey Clinic
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- Arlington, Massachusetts • Burlington, Massachusetts • Peabody, Massachusetts
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Notal Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Lakewood, Colorado • Orlando, Florida • Cincinnati, Ohio + 2 more
- Conditions
- Choroidal Neovascularization, Age-Related Maculopathy
- Interventions
- dexamethasone, ranibizumab, sham
- Drug · Biological · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Boynton Beach, Florida
- Conditions
- Geographic Atrophy, Dry Age-Related Macular Degeneration
- Interventions
- Avacincaptad Pegol, Sham
- Drug · Other
- Lead sponsor
- IVERIC bio, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Campbell, California + 48 more
- Conditions
- Complement Mediated Diseases
- Interventions
- AMY-101
- Drug
- Lead sponsor
- Amyndas Pharmaceuticals S.A.
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Retinal Imaging
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Fargo, North Dakota • Erie, Pennsylvania • Dallas, Texas + 4 more
- Conditions
- Stargardt Disease
- Interventions
- Not listed
- Lead sponsor
- AAVantgarde Bio Srl
- Industry
- Eligibility
- 8 Years to 50 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- Faricimab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 11
- States / cities
- Santa Ana, California • Orlando, Florida • Winter Haven, Florida + 8 more
- Conditions
- Geographic Atrophy
- Interventions
- NGM621, Sham Comparator
- Biological · Other
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 59 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- MC-1101, Vehicle
- Drug
- Lead sponsor
- MacuCLEAR, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Uveitic Macular Edema, Intraocular Inflammation
- Interventions
- Infliximab (intravitreal, 2.0mg/0.05ml)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- CLS-AX, Anti-VEGF
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Bakersfield, California • Mountain View, California + 8 more
- Conditions
- Atrophy, Geographic
- Interventions
- GSK933776, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Aflibercept, Triamcinolone Acetonide, Verteporfin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
- Interventions
- RN6G, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 24
- States / cities
- Campbell, California • Los Gatos, California • San Jose, California + 7 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- RetinoStat
- Drug
- Lead sponsor
- Oxford BioMedica
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2029
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
- Conditions
- Age-Related Macular Degeneration
- Interventions
- PST, ST
- Behavioral
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- AGN211745
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Cleveland, Ohio
- Conditions
- Geographic Atrophy
- Interventions
- Tinlarebant, Placebo
- Drug
- Lead sponsor
- Belite Bio, Inc
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 19 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,011 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 57
- States / cities
- Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more